Peripheral cannabinoid receptors exert a powerful inhibitory control over pain initiation, but
the endocannabinoid signal that normally engages this intrinsic analgesic mechanism is …

The medicinal properties of marijuana have been recognized for centuries, but clinical and
societal acceptance of this drug of abuse as a potential therapeutic agent remains fiercely …

Although the N-arachidonoyl ethanolamine (anandamide) binds to cannabinoid receptors
and has been implicated in the suppression of pain, its rapid catabolism in vivo by fatty acid …

The endocannabinoids anandamide and 2-arachidonoylglycerol are predominantly
regulated by the respective catabolic enzymes fatty acid amide hydrolase (FAAH) and …

Synthetic cannabinoids produce behavioral analgesia and suppress pain
neurotransmission, raising the possibility that endogenous cannabinoids serve naturally to …

Fatty acid amide hydrolase (FAAH) is an intracellular serine hydrolase that catalyzes the
cleavage of bioactive fatty acid ethanolamides, such as the endogenous cannabinoid …

While cannabinoid receptor agonists have analgesic activity in chronic pain states, they
produce a spectrum of central CB1 receptor‐mediated motor and psychotropic side effects …

Fatty acid amide hydrolase (FAAH) is the primary degradative enzyme of the
endocannabinoid anandamide (N-arachidonoylethanolamine), which activates cannabinoid …

The endogenous cannabinoid N-arachidonoyl ethanolamine (anandamide; AEA) produces
most of its pharmacological effects by binding and activating CB 1 and CB 2 cannabinoid …

Neuropathic pain elevates spinal anandamide (AEA) levels in a way further increased when
URB597, an inhibitor of AEA hydrolysis by fatty acid amide hydrolase (FAAH), is injected …